Overall impact
B (78)

Commentary

Illumina is a strong overall performer. With a 'B' rating of 78.2 for overall impact (92nd percentile compared to all companies), Illumina ranks 83rd out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 79 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 499 others. On top material causes for Illumina's industry (Pharmaceuticals & Biotech), Illumina performs well in Disease Eradication (96.6 score), Sustainable Use of Natural Resources (95.3), Access to Affordable Healthcare (95.3) and 8 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (13.9 score), Improved Mental Health (25.9) and Accountable Institutions (37.4).
Impact
Cause ILMN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1998
Employees
8,600
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Medical Equipment & Supplies
Headquarters
Ca, United States
Share classes
ILMN
Mission
To be the leading provider of integrated solutions that advance the understanding of genetics and health. Our goal is to improve human health by enabling our customers to accelerate the collection, analysis, and application of biological information.
Description
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Material causes
Ethos considers the following causes material for Illumina, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.